| Expression pattern: |
UP |
| Associated gene: |
RBFOX2, TFRC |
| Associated microRNA: |
- |
| Biological function: |
Promotes EC cell proliferation and tumor growth; confers resistance to ferroptosis (desensitizes cells to erastin/RSL3), decreasing labile iron pool and lipid peroxidation. |
| Molecular mechanism: |
Acts as a nuclear decoy binding RBFOX2 (Fox-1 C-terminal domain) to attenuate RBFOX2 binding to TFRC pre-mRNA, promoting TFRC exon-4 skipping (TFRC-S), reducing iron transport, labile iron pool, and lipid peroxide production, thereby causing ferroptosis resistance. |
| Biological pathway or process: |
proliferation (promotes); ferroptosis (inhibits); other pathway/process (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RNA Pull-Down; RIP (RNA Immunoprecipitation); Transfection; CCK8; EdU Staining; Colony Formation Assay; In Vivo Animal Model; Western Blot; Bioinformatics Analysis; Flow Cytometry（Non-apoptosis/cycle） |
| Clinical significance: |
High circRAPGEF5 expression positively correlates with FIGO stage and histological grade in EC patients. |
| Description: |
circRAPGEF5 is up-regulated in endometrial cancer and mainly nuclear. It binds the splicing factor RBFOX2 and reduces RBFOX2 binding to TFRC pre-mRNA, promoting TFRC exon-4 skipping and lowering labile iron and lipid peroxidation, thereby inhibiting ferroptosis and promoting EC cell proliferation and tumor growth. |
| Confidence score: |
0.8445 |